Calendrier des promotions Alpine Immune Sciences, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Paramètres de base
IPO date
2015-06-17
ISIN
US02083G1004
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 16.49 | 1 |
P/BV | 2.96 | 6 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -8.43 | 0 |
ROE | -9.81 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.227 | 10 |
Debt/Ratio | 0.026 | 10 |
Debt/Equity | 0.1643 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 3363.29 | 10 |
Rentabilité Ebitda, % | 5.24 | 1 |
Rentabilité EPS, % | -72.26 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 7.7 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 7.7 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.30d | 7.7 $ | 7.7 $ | 7.7 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.90d | 7.7 $ | 7.7 $ | 7.7 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.180d | 7.7 $ | 7.7 $ | 7.7 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.1y | 7.7 $ | 7.5 $ | 64.97 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.3y | 8 $ | 5.45 $ | 64.97 $ | -3.75 % | 0 % | 0 % |
common.calendar.number_days.5y | 10.5 $ | 5.45 $ | 64.97 $ | -26.67 % | 0 % | 0 % |
common.calendar.number_days.10y | 2.04 $ | 2.04 $ | 64.97 $ | 377.45 % | 0 % | 0 % |
common.calendar.number_days.ytd | 7.7 $ | 7.7 $ | 7.7 $ | 0 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Mitchell H. Gold M.D. | Executive Chairman & CEO | 1.02M | 1968 (57 années) |
Dr. Stanford Peng M.D., Ph.D. | President and Head of Research & Development | 940.1k | 1971 (54 année) |
Mr. Paul Rickey | Senior VP, CFO, Treasurer & Secretary | 691.1k | 1979 (46 années) |
Dr. Remy Durand Ph.D. | Chief Business Officer | N/A | 1985 (40 années) |
Ms. M. Christina Yi | Chief Technology Officer | N/A | 1977 (48 années) |
Temre Johnson | Head of IR & Corporate Communications | ||
Dr. Wolfgang Dummer M.D., Ph.D. | Chief Medical Officer | 1966 (59 années) |
Informations sur l'entreprise
Adresse: United States, Seattle. WA, 188 East Blaine Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.alpineimmunesciences.com
Site web: https://www.alpineimmunesciences.com